Trials / Completed
CompletedNCT03427151
Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- ImmuPharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main study IP-005.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IPP-201101 | 200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks. |
Timeline
- Start date
- 2018-02-27
- Primary completion
- 2019-02-05
- Completion
- 2019-02-05
- First posted
- 2018-02-09
- Last updated
- 2019-04-11
Locations
14 sites across 7 countries: United States, Czechia, France, Germany, Hungary, Mauritius, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03427151. Inclusion in this directory is not an endorsement.